Biogen Inc. Announces Executive and Board Changes
Ticker: BIIB · Form: 8-K · Filed: 2024-09-12T00:00:00.000Z
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: BIIB
TL;DR
Biogen shakes up exec team and board. New faces, new plans?
AI Summary
Biogen Inc. announced on September 11, 2024, changes in its executive team and board of directors. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives.
Why It Matters
Changes in leadership and board composition can signal shifts in company strategy, governance, and future direction.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and operational stability.
Key Players & Entities
- Biogen Inc. (company) — Registrant
- September 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Cambridge, Massachusetts (location) — Principal executive office address
FAQ
What specific roles have been affected by the departures mentioned in the filing?
The filing indicates the departure of 'certain officers' and 'directors' but does not specify the exact roles or names of those departing in this section.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated September 11, 2024.
What is Biogen Inc.'s state of incorporation?
Biogen Inc. is incorporated in Delaware.
Where are Biogen Inc.'s principal executive offices located?
Biogen Inc.'s principal executive offices are located at 225 Binney Street, Cambridge, Massachusetts 02142.
What type of report is this filing?
This filing is a Current Report on Form 8-K.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-09-12 07:31:32
Key Financial Figures
- $0.0005 — nge on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Se
Filing Documents
- d896502d8k.htm (8-K) — 22KB
- g896502g07w87.jpg (GRAPHIC) — 8KB
- 0001193125-24-217633.txt ( ) — 160KB
- biib-20240911.xsd (EX-101.SCH) — 3KB
- biib-20240911_lab.xml (EX-101.LAB) — 17KB
- biib-20240911_pre.xml (EX-101.PRE) — 11KB
- d896502d8k_htm.xml (XML) — 3KB
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biogen Inc. By: /s/ Wendell Taylor Wendell Taylor Secretary Date: September 12, 2024 3